YD Bio Ltd
YD Bio Ltd is a U.S.-anchored biotechnology and medical-laboratory services company with operations spanning regulated diagnostics, life science clinical services, and healthcare product commercialization. The company works through an affiliate laboratory and partner-based commercial channels across the United States and Asia, with additional regulated ocular health and consumer health activities.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2023–2025
Liiketoiminta
Osuus liikevaihdostaMethylation-based cancer testing and related laboratory diagnostics services.
Sample collection, testing workflows, and lab-based reporting services.
Compliance-focused distribution of medical and life science products.
Supply chain and regulatory liaison services for pharma and biotech partners.
Commercialization and distribution of regulated eye-health and consumer products.
Tuotteet
Raportoitu · osuus liikevaihdosta- Medical and Related Products47,0 %
- Drugs37,4 %
- Beauty Products8,4 %
- Contact Lenses5,9 %
- Nutritional Products0,9 %
- Supplements0,4 %
Lähde: 20-F FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
YD Bio serves biopharma companies, clinical research participants, and healthcare channel partners that need regulated laboratory, distribution, and commercialization support. Its testing services are used in oncology-related screening and diagnostic workflows, while its life science services are aimed at pharmaceutical and biotechnology customers navigating regulatory and supply-chain requirements. The ocular health and consumer health businesses address commercial healthcare buyers and end-market distribution channels in Asia and the U.S.
They buy regulatory liaison, clinical supply chain, and partner support services to move programs through development and compliance steps.
They use oncology testing services and lab workflows for screening and clinical decision support.
They source ocular health and related regulated health products for distribution and commercialization.
They purchase consumer health products through commercial distribution platforms in Asia.
Strategia
YD Bio is focused on standardizing its service offerings, scaling operations, and formalizing partnership agreements to expand recurring business. Its model relies on partner-led execution across diagnostics, supply chain services, and regulated commercialization, which can widen reach without fully internalizing every function. The company also appears to be building a broader healthcare platform that links diagnostics, clinical services, and commercial product distribution.
A more repeatable service model supports scale and easier partner onboarding.
Contracted partner relationships help create recurring revenue and operational visibility.
Broader coverage increases addressable market and utilization of lab workflows.
Combining diagnostics, services, and commercialization broadens the business base.
Maantiede
YD Bio is headquartered in Taiwan, operates as a U.S.-anchored public company, and runs business activities in both the United States and Asia. Its oncology testing coverage currently spans 44 U.S. states plus Washington, D.C. and Guam, while other commercialization and distribution activities extend into Asian markets. Geography matters because the business depends on local laboratory rules, import/export controls, and partner execution across multiple regulated markets.
Riskit
YD Bio depends on regulated markets, outside suppliers, and partner execution, so regulatory delays or supply interruptions can affect operations quickly. The company also faces typical biotechnology commercialization risk because it has not yet completed clinical trials or secured broad product approvals. As a cross-border healthcare business, it is exposed to changes in U.S. and foreign import, export, and medical-device rules.
- Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Korkea
Products and services are subject to extensive U.S. and foreign health regulations, and the company notes it has not completed clinical trials or secured product approvals.
Kohdistuu: Diagnostics and product commercialization
- Supplier concentrationVaikutus: KorkeaTodennäköisyys: Korkea
Two suppliers represented a large share of purchases, creating potential disruption if either source is interrupted.
Kohdistuu: Medical products and services procurement
- Commercialization uncertaintyVaikutus: KorkeaTodennäköisyys: Kohtalainen
Biotechnology offerings may fail to reach market or achieve marketable product status.
Kohdistuu: Pipeline and product launches
- Cross-border regulatory complexityVaikutus: KeskitasoTodennäköisyys: Korkea
U.S. and foreign rules govern export, import, and distribution of medical products and cancer early-detection services.
Kohdistuu: United States and Asia operations
- Partner execution riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
A partner-led model depends on external parties to deliver, scale, and support client relationships.
Kohdistuu: Clinical services and commercialization partnerships
Kirjanpito
Harkinnanvaraiset erätPublic and private placement warrants are classified as liabilities and remeasured each period, creating non-cash earnings volatility.
Vaikutus: Fair value changes flow through the statement of operations
The merger is accounted for as a recapitalization, not a conventional acquisition, which affects comparability and balance-sheet presentation.
Vaikutus: No purchase accounting goodwill from the transaction
Revenue, liabilities, and disclosures rely on management assumptions in an early-stage regulated business.
Vaikutus: Can materially change reported period results
The company can defer certain new accounting standards, which may affect timing and comparability of adoption.
Vaikutus: Differences versus larger peers in disclosure and timing
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
KALA BIO, Inc
KALA · Pharmaceutical Preparations
Yubo International Biotech Ltd
YBGJ · Electromedical & Electrotherapeutic Apparatus
Yubo International Biotech Ltd is a U.S.-listed holding company whose operating business is conducted in China through Yubo International Biotech (Beijing)…
CytoDyn Inc.
CYDY · Pharmaceutical Preparations
SL Science Holding Ltd
SLBT · Biological Products, (No Diagnostic Substances)
SL Science Holding Ltd is a U.S.-listed biotechnology and biological products company based in Taipei, Taiwan, operating through its SL Bio business.
Cardio Diagnostics Holdings, Inc.
CDIOW · In Vitro & In Vivo Diagnostic Substances
Jyong Biotech Ltd.
MENS · Pharmaceutical Preparations
Päivitetty: 28.9.2026